EQUITY RESEARCH - ANALYST MEETING

THAILAND / HEALTH CARE SERVICES

BUMRUNGRAD HOSPITAL

BHTB



TARGET PRICE

UP/DOWNSIDE

TP vs CONSENSUS

CLOSE

FSSIA ESG rating



THB300.00

THB227.00

+32.2%

+5.2%

Key takeaways from analyst meeting

3Q23 highlights

- การประชุมฯ โดยรวม เป็นกลาง
- ผู้บริหารให้รายละเอียดเกี่ยวกับการเติบโตใน 3Q23 เมื่อเทียบกับ 3Q22 เพิ่มเติม รายได้ จากผู้ป่วยจากต่างประเทศโต 16% y-y โดยได้ปัจจัยหนุนส่วนมากจากผู้ป่วยชาว ตะวัน[ื]ออกกลาง (+31% y-y) อย่างไรก็ดีรายได้จากอินโดจีนลดลง 4% y-y จากการชะลอ ้ ตัวของปริมาณผู้ป่วยชาวพม่า ในขณะที่รายได้จากผู้ป่วยชาวไทยและต่างชาติยังคงอยู่ใน เกณฑ์ดีโดยปรับขึ้น 20% y-y และ 27% y-y ตามลำดับ
- 3 ประเทศที่ให้รายได้จากผู้ป่วยจากต่างประเทศสูงสุดใน 3Q23 ได้แก่การ์ตา (+85% yy) พม่า (-9% y-y) และคูเวต (-38% y-y) ทั้งนี้ผู้ป่วยชาวจีนอยู่ในลำดับที่ 10 พร้อมอัตรา การเติบโตของรายได้ที่ 21% y-y
- รายได้จากผู้ป่วยชาวพม่าลดลง y-y จากปัญหาความวุ่นวายทางการเมือง ในขณะที่รายได้ จากผู้ป่วยชาวดูเวตลดลงเนื่องจากผู้ป่วยมีการย้ายไปรักษาที่ยุโรปและสหรัฐฯ
- BH บันทึกค่าใช้จ่ายโบนัสพนักงานค้างจ่ายในไตรมาสนี้ ถ้าหักรายการดังกล่าว EBITDA margin จะเพิ่มเป็น 40.5% จาก 38.9%
- ผู้บริหารตั้งเป้าการเติบโตของรายได้ 4Q23 เป็นตัวเลขสองหลักเมื่อเทียบ y-y นับว่าลดลง เมื่อเทียบกับในช่วง 9M23 จากผลกระทบด้านฤดูกาล
- BH คาดว่าความสามารถในการรองรับผู้ป่วยในจะเพิ่มเป็น 526 เตียงใน 4Q23 จาก ค่าเฉลี่ยที่ 493 เตียงใน 3Q23 นอกจากนี้ BH ยังวางแผนเพิ่มเตียงในห้อง ICU อีก 12 เตียงในปี 2024
- ในด้านการขยายธุรกิจ BH วางแผนเปิด BI Hospital Annex และย้าย Women and Children Center ไปที่นั่นในปี 2024 นอกจากนี้บริษัทฯ ยังมีกำหนดเปิด Soi 1 project building ตีกที่ 2 พร้อมความสามารถในการรองรับผู้ป่วยใน 59 เตียงในกลางปี 2025 และ จะเปิดตึกที่ 3 สำหรับ The Oncology Institute หลังจากนั้น ท้ายที่สุดบริษัทฯ มีกำหนด เปิดโครงการในภูเก็ตโดยจะมีงบลงทุน 3.8พัน ลบ. และความสามารถในการรับผู้ป่วยใน 150-250 เตียงในปลายปี 2025
- VitalLife เป็นหนึ่งในปัจจัยหนุนการเติบโตที่สำคัญในช่วง 9M23 โดยให้ส่วนแบ่งรายได้ 4% ในช่วงดังกล่าวพร้อมอัตราการเติบโตของรายได้ที่ 35% y-y เมื่อเทียบกับผล ประกอบการรวมของ BH กิจการดังกล่าวมี EBITDA margin ดีกว่าที่ 43% และอัตรา กำไรสุทธิที่ 34%

Recommendation

ราคาหุ้นของ BH ปรับตัวลดลง 9% หลังประกาศผลประกอบการ 3Q23 จากความกังวล เกี่ยวกั่บกำไรที่น่าจะโตช้าใน 4Q23 จากฤดูกาลที่ซบเซา เราเห็นว่าประเด็นดังกล่าวเป็น โอกาสในการสะสมเนื่องหุ้นมีการซื้อขายที่ 26x ของค่า 2024E P/E (เทียบกับค่าเฉลี่ย 5 ปีที่ 32x) BH มีศักยภาพในการจับการเติบโตใหม่จากผู้ป่วยชาวซาอุดิอาระเบียซึ่งสร้าง รายได้ 1% ของรายได้รวมในช่วง 9M23 ในขณะที่บริษัทฯ ตั้งเป้าให้รายได้จากผู้ป่วยชาว ซาอุดิอาระเบียกระโดดเพิ่ม 2.7x ในปี 2024

KEY STOCK DATA

YE Dec (THB m)	2022	2023E	2024E	2025E
Revenue	20,721	25,629	26,662	28,282
Net profit	4,938	6,822	7,066	7,552
EPS (THB)	6.21	8.57	8.88	9.49
vs Consensus (%)	-	1.8	(1.3)	(0.8)
EBITDA	7,127	9,527	9,909	10,562
Recurring net profit	4,941	6,762	7,066	7,552
Core EPS (THB)	6.21	8.50	8.88	9.49
EPS growth (%)	287.9	36.8	4.5	6.9
Core P/E (x)	36.6	26.7	25.6	23.9
Dividend yield (%)	1.4	1.5	2.2	2.3
EV/EBITDA (x)	24.2	17.6	16.7	15.3
Price/book (x)	9.2	7.6	6.8	6.0
Net debt/Equity (%)	(41.1)	(54.3)	(58.6)	(62.7)
ROE (%)	26.7	31.1	28.0	26.6



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	(14.0)	(7.3)	(0.9)
Relative to country (%)	(10.0)	2.6	16.1
Mkt cap (USD m)			5,002
3m avg. daily turnover (USD m)			18.9
Free float (%)			65
Major shareholder		Thai N\	/DR (16%)
12m high/low (THB)		272	.00/203.00
Issued shares (m)			922.70

Sources: Bloomberg consensus; FSSIA estimates




Teerapol Udomvej, CFA

Fundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969


PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

Exhibit 1: International patient revenue, quarterly



Source: BH

Exhibit 3: International patient revenue, yearly




Sources: BH; FSSIA estimates

Exhibit 5: EBITDA margin, quarterly




Source: BH

Exhibit 2: Thai patient revenue, quarterly




Source: BH

Exhibit 4: Thai patient revenue, yearly



Sources: BH; FSSIA estimates

Exhibit 6: Discount rate has converted to pre-Covid level



Sources: BH; FSSIA estimates

Financial Statements

Bumrungrad Hospital

Profit and Loss (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025E
Revenue	12,460	20,721	25,629	26,662	28,282
Cost of goods sold	(7,731)	(11,099)	(13,056)	(13,614)	(14,400)
Gross profit	4,729	9,621	12,573	13,048	13,882
Other operating income	144	187	187	193	198
Operating costs	(3,296)	(3,798)	(4,390)	(4,567)	(4,845)
Operating EBITDA	2,758	7,127	9,527	9,909	10,562
Depreciation	(1,180)	(1,117)	(1,157)	(1,236)	(1,327)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	1,578	6,010	8,370	8,673	9,235
Net financing costs	(51)	42	131	208	254
Associates	(12)	(1)	(1)	(1)	(1)
Recurring non-operating income	(12)	(1)	(1)	(1)	(1)
Non-recurring items	(58)	(3)	60	0	C
Profit before tax	1,456	6,049	8,560	8,881	9,488
Гах	(216)	(1,072)	(1,700)	(1,776)	(1,898)
Profit after tax	1,240	4,977	6,860	7,105	7,591
Minority interests	(24)	(39)	(39)	(39)	(39)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	1,216	4,938	6,822	7,066	7,552
Non-recurring items & goodwill (net)	58	3	(60)	0	0
Recurring net profit	1,274	4,941	6,762	7,066	7,552
Per share (THB)					
Recurring EPS *	1.60	6.21	8.50	8.88	9.49
Reported EPS	1.53	6.21	8.57	8.88	9.49
DPS .	3.20	3.20	3.50	5.10	5.33
Diluted shares (used to calculate per share data)	796	796	796	796	796
Growth					
Revenue (%)	0.8	66.3	23.7	4.0	6.1
Operating EBITDA (%)	6.5	158.5	33.7	4.0	6.6
Operating EBIT (%)	15.3	281.0	39.3	3.6	6.5
Recurring EPS (%)	6.2	287.9	36.8	4.5	6.9
Reported EPS (%)	1.0	306.2	38.1	3.6	6.9
Operating performance					
Gross margin inc. depreciation (%)	38.0	46.4	49.1	48.9	49.1
Gross margin exc. depreciation (%)	47.4	51.8	53.6	53.6	53.8
Operating EBITDA margin (%)	22.1	34.4	37.2	37.2	37.3
Operating EBIT margin (%)	12.7	29.0	32.7	32.5	32.7
Net margin (%)	10.2	23.8	26.4	26.5	26.7
Effective tax rate (%)	14.1	17.7	20.0	20.0	20.0
Dividend payout on recurring profit (%)	199.7	51.5	41.2	57.4	56.1
nterest cover (X)	30.7	(141.7)	(64.1)	(41.6)	(36.4)
nventory days	17.7	11.9	11.0	11.7	11.6
Debtor days	53.7	36.3	36.0	32.9	31.0
Creditor days	42.0	34.6	36.5	38.9	38.6
Operating ROIC (%)	10.6	40.6	56.9	60.4	63.3
ROIC (%)	10.0	39.1	54.9	58.2	61.1
ROE (%)	7.1	26.7	31.1	28.0	26.6
ROA (%)	6.0	21.9	25.1	22.6	21.7
Pre exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2021	2022	2023E	2024E	2025E
Γhai patient revenue	6,661	7,536	8,591	8,848	9,291
nternational patient revenue	5,743	13,110	16,960	17,735	18,911
Other revenue	56	75	78	79	80

Sources: Bumrungrad Hospital; FSSIA estimates

Financial Statements

Bumrungrad Hospital

Bulliuligiau Flospitai					
Cash Flow (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025E
Recurring net profit	1,274	4,941	6,762	7,066	7,552
Depreciation	1,180	1,117	1,157	1,236	1,327
Associates & minorities	-	-	-	-	-
Other non-cash items	318	26	99	39	39
Change in working capital	897	131	911	144	221
Cash flow from operations	3,668	6,216	8,928	8,484	9,138
Capex - maintenance	(928)	(1,170)	(1,281)	(1,600)	(1,697)
Capex - new investment	-	-	-	-	-
Net acquisitions & disposals	74	0	0	0	0
Other investments (net)	- (0.50)	-	-	-	-
Cash flow from investing	(853)	(1,170)	(1,281)	(1,600)	(1,697)
Dividends paid	(2,545)	(2,543)	(2,785)	(4,057)	(4,240)
Equity finance	0 (0.510)	0	0	0	0
Debt finance	(2,516)	(8)	0	0 0	0
Other financing cash flows	44 (5.017)	(155)			(4.240)
Cash flow from financing	(5,017)	(2,705)	(2,785)	(4,057)	(4,240)
Non-recurring cash flows	0	0	0	0	0
Other adjustments	0	0	0	0	0
Net other adjustments Movement in cash	(2,203)	2,341	4,861	2,828	3,201
Free cash flow to firm (FCFF)	, , ,	·	·	•	
Free cash flow to firm (FCFF)	2,934.46 342.35	5,049.59 4,882.92	7,648.39 7,646.49	6,886.53 6,884.63	7,443.06 7,441.17
	342.33	4,002.92	7,040.49	0,004.03	7,441.17
Per share (THB)					
FCFF per share	3.18	5.47	8.29	7.46	8.07
FCFE per share	0.37 3.48	5.29 7.65	8.29 10.07	7.46 10.48	8.06 11.21
Recurring cash flow per share	3.40	7.05	10.07	10.46	11.21
Balance Sheet (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025E
Fangible fixed assets (gross)	25,744	26,652	27,933	29,533	31,230
Less: Accumulated depreciation	(13,425)	(14,236)	(15,393)	(16,630)	(17,956)
Tangible fixed assets (net)	12,319	12,416	12,540	12,904	13,274
ntangible fixed assets (net)	71	61	61	61	61
Long-term financial assets	,,	-	-	-	-
nvest. in associates & subsidiaries	1	1	1	1	1
Cash & equivalents	5,936	8,276	13,137	15,965	19,167
A/C receivable	1,461	2,658	2,402	2,402	2,402
nventories	328	326	388	404	427
Other current assets	338	159	196	204	217
Current assets	8,062	11,419	16,124	18,975	22,212
Other assets	404	362	362	362	362
Total assets	20,857	24,259	29,088	32,303	35,910
Common equity	17,286	19,705	23,742	26,751	30,063
Minorities etc.	332	300	338	377	415
Total shareholders' equity	17,618	20,005	24,080	27,128	30,479
Long term debt	71	63	63	63	63
Other long-term liabilities	924	799	799	799	799
Long-term liabilities	995	862	862	862	862
A/C payable	805	1,085	1,293	1,346	1,421
Short term debt	0	0	0	0	0
Other current liabilities	1,439	2,306	2,853	2,968	3,148
Current liabilities	2,244	3,391	4,146	4,313	4,569
Total liabilities and shareholders' equity	20,857	24,259	29,088	32,303	35,910
Net working capital	(117)	(249)	(1,160)	(1,303)	(1,524)
nvested capital	12,677	12,591	11,805	12,025	12,174
Includes convertibles and preferred stock which is bei		,	,	,-	,
Por charo (THR)					
Per share (THB) Book value per share	21.72	24.76	20.04	32.62	27 70
•	21.72	24.76	29.84	33.62 33.54	37.78 37.70
Tangible book value per share Financial strength	21.63	24.69	29.76	33.54	37.70
•	(00.0)	(44.4)	(F4.0)	(50.0)	/00 T
Net debt/equity (%)	(33.3)	(41.1)	(54.3)	(58.6)	(62.7)
Net debt/total assets (%)	(28.1)	(33.9)	(44.9)	(49.2)	(53.2)
Current ratio (x)	3.6	3.4	3.9	4.4	4.9
CF interest cover (x)	7.7	(114.1)	(57.6)	(32.1)	(28.3)
/aluation	2021	2022	2023E	2024E	2025E
Recurring P/E (x) *	141.8	36.6	26.7	25.6	23.9
Recurring P/E @ target price (x) *	187.4	48.3	35.3	33.8	31.6
Reported P/E (x)	148.6	36.6	26.5	25.6	23.9
Dividend yield (%)	1.4	1.4	1.5	2.2	2.3
Price/book (x)	10.4	9.2	7.6	6.8	6.0
		9.2	7.6	6.8	6.0
Price/tangible book (x)	10.5				
Price/tangible book (x) EV/EBITDA (x) **	10.5 63.5	24.2	17.6	16.7	15.3
• , ,			17.6 23.7	16.7 22.5	15.3 20.8
EV/EBITDA (x) **	63.5	24.2			

Sources: Bumrungrad Hospital; FSSIA estimates

Bumrungrad Hospital PCL (BH TB)

FSSIA ESG rating

★ ★ ★

Exhibit 7: FSSIA ESG score implication

51.21 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
****	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 8: ESG – peer comparison

	FSSIA			Dome	stic ratings	;			Global ratings					Bloomberg	
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
всн	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Υ	Y	Υ	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
вн	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35	-		59.57	21.00	2.34	50.24
PR9	54.08		Υ	Υ	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified			-					
RAM	11.75				3.00			High		-					
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

 $Sources: \underline{SETTRADE.com}; FSSIA's compilation$

Exhibit 9: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	0.85	1.30	1.60	1.49	1.73	3.35	3.58	5.08
BESG environmental pillar score	0.00	1.75	1.75	1.75	1.75	3.21	3.73	3.73
BESG social pillar score	0.18	0.18	0.38	0.38	0.85	3.19	3.25	6.43
BESG governance pillar score	3.25	3.57	4.35	3.81	3.55	3.73	4.07	3.97
ESG disclosure score	31.24	32.94	35.78	35.78	36.40	47.68	47.79	47.79
Environmental disclosure score	0.42	5.53	8.91	8.91	9.76	35.43	35.76	35.76
Social disclosure score	12.03	12.03	17.17	17.17	18.20	26.39	26.39	26.39
Governance disclosure score	81.10	81.10	81.10	81.10	81.10	81.10	81.10	81.10
Environmental								
Emissions reduction initiatives	No	No	No	No	No	Yes	Yes	Yes
Climate change policy	No	No	No	No	No	Yes	Yes	Yes
Climate change opportunities discussed	No							
Risks of climate change discussed	No	No	No	No	No	No	Yes	Yes
GHG scope 1	_	_	_	_	_	_	_	_
GHG scope 2 location-based	_	_	_	_	_	_	_	_
GHG Scope 3	_	_	_	_	_	_	_	_
Carbon per unit of production	_	_	_	_	_	_	_	_
Biodiversity policy	No							
Energy efficiency policy	Yes							
Total energy consumption	_	0	0	0	0	0	0	0
Renewable energy use	_	_	_	_	_	_	_	_
Electricity used	_	_	_	_	_	_	_	_
Fuel used - natural gas	_	_	_	_	_	_		_

 $Sources: Bloomberg; FSSIA's \ compilation$

Exhibit 10: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No	No	No	No	No	No
Waste reduction policy	No	No	No	No	No	Yes	Yes	Yes
Hazardous waste	_	_	_	_	_	_	_	_
Total waste	_	_	_	_	_	_	_	_
Waste recycled		_	_	_	_	_	_	_
Waste sent to landfills	_	_	_	_	_	_	_	_
Environmental supply chain management	No	No	No	No	No	Yes	Yes	Yes
Water policy	No	No	No	No	Yes	Yes	Yes	Yes
Water consumption	_	_	_	_	_	_	_	_
Social								
Human rights policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Policy against child labor	No	No	No	No	Yes	Yes	Yes	Yes
Quality assurance and recall policy	No	No	No	No	No	Yes	Yes	Yes
Consumer data protection policy	No	No	No	No	No	Yes	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Gender pay gap breakout	No	No	No	No	No	No	No	No
Pct women in workforce		_	_	_	_	_		
Pct disabled in workforce	_	_	_	_	_	_	_	_
Business ethics policy	No	No	No	No	No	Yes	Yes	Yes
Anti-bribery ethics policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Health and safety policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lost time incident rate - employees		_	_	_	_	_	_	
Total recordable incident rate - employees	_	_		_	_	_	_	_
Training policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Fair remuneration policy	No	No	No	No	No	No	No	No
Number of employees – CSR	140	140	3,984	3,980	4,088	3,782	3,455	4,219
Employee turnover pct			3,304	3,960	4,000	7	7	4,213
Total hours spent by firm - employee training			247,805	268,252	283,707	207,353	195,380	234,480
Social supply chain management	No	No	No	No	203,707 No	Yes	Yes	Yes
Governance	NO	INU	INU	NO	INU	162	162	163
Board size	11	11	11	11	10	10	11	11
	4	11	11	4	4	4	5	5
No. of independent directors (ID)		3						
No. of women on board	3		3	3	3	3	3	3
No. of non-executive directors on board	8	8 Van	9	9	9	9	10	10
Company conducts board evaluations	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
No. of board meetings for the year	5	4	6	4	4	7	4	- 4
Board meeting attendance pct	91	93	97	87	88	87	95	98
Board duration (years)	3	3	3	3	3	3	3	
Director share ownership guidelines	No	No	No	No	No	No	No	No
Age of the youngest director	42	43	49	50	51	52	27	28
Age of the oldest director	75	75	78	79	79	80	78	79
No. of executives / company managers	7	6	6	6	4	4	4	
No. of female executives	1	2	2	3	3	3	3	3
Executive share ownership guidelines	No	No	No	No	No	No	No	No
Size of audit committee	3	3	3	3	3	3	4	4
No. of ID on audit committee	3	3	3	3	3	3	4	4
Audit committee meetings	4	4	4	5	5	4	4	4
Audit meeting attendance %	100	92	92	87	100	100	87	100
Size of compensation committee	3	3	3	3	3	3	3	3
No. of ID on compensation committee	1	1	1	1	1	1	1	1
No. of compensation committee meetings	1	1	5	3	2	2	3	3
Compensation meeting attendance %	100	100	100	100	100	83	100	100
Size of nomination committee	3	3	3	3	3	3	3	
No. of nomination committee meetings	1	1	5	3	2	2	3	3
Nomination meeting attendance %	100	100	100	100	100	83	100	100
Sustainability governance								
Verification type	No	No	No	No	No	No	No	No

 $Sources: Bloomberg; FSSIA's \ compilation$

Disclaimer for ESG scoring

ESG score	Methodolog	У			Rating					
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process base from the ann Only the top- inclusion.	ed on the compual S&P Globa ranked compa	ransparent, rules-based co panies' Total Sustainability Il Corporate Sustainability nies within each industry a	Scores resulting Assessment (CSA). Assessment for	Sustainability ESG Score of scoring compa selected from	Assessment less than 45 any are disqu the Eligible I		I. Companies Global ESG s Instituents of	s with an S&P Score of the h the DJSI indic	ighest ces are
Sustainability Investment List (THSI) by The Stock Exchange of Thailand (SET)	managing bu Candidates r 1) no irregula float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with tra must pass the part rading of the shareholders, ome key disquependent direct related to CG,	ity in Environmental and Sinsparency in Governance or emptive criteria, with two e board members and exee and combined holding mulalifying criteria include: 1) ors and free float violation; social & environmental imparnings in red for > 3 years	, updated annually. vo crucial conditions: cutives; and 2) free ist be >15% of paid- CG score of below ; 3) executives' pacts; 4) equity in	To be eligible for <u>THSI inclusion</u> , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJ: during the assessment year. The scoring will be fairly weighted against nature of the relevant industry and materiality. <u>SETTHSI Index</u> is extended from the THSI companies whose 1) marke capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weigh maximum, and no cap for number of stocks.					
by Thai Institute of Directors Association (Thai IOD)	annually by t Thailand (SE	he Thai IOD, v	in sustainable developme vith support from the Stock are from the perspective .	Exchange of	Good (80-89), and not rated equitable trea	3 for Good for scores be ment of sha 25%); 4) dis	egories: 5 for E (70-79), 2 for F elow 50. Weigh reholders (weig closure & trans	air (60-69), 1 itings include ght 25% com	for Pass (60- : 1) the rights; bined); 3) the	-69), ; 2) and role of
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment are transparent a out of five the assessment the meeting advance circul rights can be e transparency a	e incorporated and sufficiently e CG compone criteria cover A date (45%), an ation of sufficient exercised. The se and verifiability; as	hich shareholders' rights a into business operations a disclosed. All form importants to be evaluated annual (SM procedures before the dafter the meeting (10%), information for voting; and 2) found assesses 1) the ease of a day openness for Q&A. The tentain discussion issues, resolution.	and information is ant elements of two ally. The e meeting (45%), at . (The first assesses 1) facilitating how voting attending meetings; 2) third involves the						
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishmer policies. The (Companies de Declaration of Certification, in managers and	nt of key control Certification is eciding to become Intent to kick off a cluding risk asse	hecklist include corruption ols, and the monitoring and a good for three years. e a CAC certified member start an 18-month deadline to submi ssment, in place of policy and blishment of whistleblowing ch- stakeholders.)	d developing of t by submitting a it the CAC Checklist for control, training of	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.					
Morningstar Sustainalytics	based on an risk is unmar regulatory filing	assessment on aged. Sources gs, news and other	k rating provides an overa f how much of a company' to be reviewed include corpora er media, NGO reports/website , ESG controversies, issuer fee	's exposure to ESG ate publications and es, multi-sector			ng score is the ne higher ESG Medium			he
		uality & peer revie			0-10	10-20	20-30	30-40	40+	
ESG Book	positioned to the principle helps explair over-weightin	outperform ov of financial ma n future risk-ad	ustainable companies that fer the long term. The meth teriality including informati justed performance. Mater h higher materiality and rel by basis.	hodology considers ion that significantly riality is applied by	The total ESG score is calculated as a weighted sum of the features scores using materiality-based weights. The score is scaled between 0 and 100 with higher scores indicating better performance.					
<u>MSCI</u>			neasure a company's mana							logy to
	AAA	8.571-10.000	l ande	Incoding the least of the	annair - th	alamiti : 501	S mindroI	iti a -		
	AA	7.143-8.570	Leader:	leading its industry in n	iariaging the most	əigiiiiicant ESC	noko anu oppor	turnues		
	Α	5.714-7.142								
	BBB	4.286-5.713	Average:	a mixed or unexception industry peers	nal track record of r	nanaging the n	nost significant E	SG risks and o	pportunities rela	tive to
	ВВ	2.857-4.285								
	В	1.429-2.856	l aggord.	lagging its industry bas	ad an its high area	sure and fail	o to manage size	nificant ESC ===	ke	
	CCC	0.000-1.428	Laggard:	ayying its industry bas		oure and failul	e to manage sigr	IIIICAIIL ESG IIS	no .	
Moody's ESG solutions	believes that	a company in	ree to which companies tal tegrating ESG factors into r shareholders over the me	its business model ar						
Refinitiv ESG rating	based on pu	blicly available	and objectively measure a and auditable data. The s a publicly. (Score ratings are	core ranges from 0 to	100 on relative	ESG perform	nance and insu	fficient degre		
S&P Global			e is a relative score measun the same industry classif				ent of ESG risk	s, opportuniti	es, and impac	rts
Bloomberg	ESG Score		Bloomberg score evaluati score is based on Bloomb of Pillar Scores, where the	perg's view of ESG fin	ancial materiality	. The score	is a weighted o	eneralized n	nean (power n	nean)
Bloomberg	ESG Disclos	ure Score	Disclosure of a company's every data point, measuring							ure of

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
09-Dec-2020	BUY	150.00	04-Mar-2022	BUY	190.00	10-Nov-2022	BUY	255.00
07-May-2021	BUY	160.00	09-May-2022	BUY	205.00	21-Feb-2023	BUY	260.00
20-Aug-2021	BUY	155.00	01-Jul-2022	BUY	210.00	09-May-2023	BUY	280.00
04-Nov-2021	BUY	170.00	22-Aug-2022	BUY	235.00	17-Aug-2023	BUY	300.00

Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Bumrungrad Hospital	ВН ТВ	THB 227.00	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher medical fee discount promotions, leading to a weaker EBITDA margin.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 14-Nov-2023 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.